华森制药：公司获得克唑替尼胶囊药品注册证书

Core Viewpoint - Huason Pharmaceutical has received the drug registration certificate for Crizotinib capsules from the National Medical Products Administration, marking a significant milestone in its oncology product portfolio [1] Group 1: Company Developments - The approval of Crizotinib capsules allows Huason Pharmaceutical to treat ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients, as well as ROS1-positive advanced NSCLC patients [1] - Huason Pharmaceutical becomes the second company in the country to obtain approval for this product, filling a gap in its oncology offerings [1] - The introduction of this drug is expected to enhance the company's brand influence in the oncology segment [1]